{
    "clinical_study": {
        "@rank": "46750", 
        "arm_group": {
            "arm_group_label": "Bevacizumab plus chemotherapy\uff08XELOX or FOLFOX\uff09", 
            "arm_group_type": "Experimental", 
            "description": "Bevacizumab plus XELOX (Bevacizumab 7.5mg/kg d1;Xeloda 2g/m2 d1-14 divided into two times;Oxaliplatin 130mg/m2 d1;repeated in 21 days) Bevacizumab plus FOLFOX (Oxaliplatin 85mg/ m2 ivgtt d1;CF 200mg/ m2 ivgtt d1;Bevacizumab 5mg/kg ivgtt d1  5-FU 400mg /m2 ivgtt d1;5-FU 2400mg/m2  CIV 48h;repeated in 14 days)"
        }, 
        "brief_summary": {
            "textblock": "This  study evaluates the relationship of biomarker expression and efficacy of bevacizumab\n      plus chemotherapy in patients with unresectable/metastatic colorectal cancer. Before the\n      treatment, the investigators detect the VEGF-A,VEGF-C,VEGF-D,VEGFR-1,VEGFR-2,VEGFR-3\n      expression in tumor tissue by IHC and detect those protein expression level in plasma by\n      ELISA. After at least 6 weeks treatment, the investigators detect again VEGF-A,VEGF-C,VEGF-D\n      expression level in plasma by ELISA. The aim of the study is to identify whether those\n      biomarkers could predict Bevacizumab efficacy."
        }, 
        "brief_title": "Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  More than 18-years old,male or female\n\n          -  Pathologically approved as unresectable/metastatic colorectal cancer\n\n          -  KPS > 70% or ECOG 0-2\n\n          -  HGB > 80 g/L, NEUT \u2265 1.5x109 /L, PLT \u2265 80x109 /L; CR < 1.5 x Upper normality\uff0c\n\n          -  TB < 1.5 X Upper normality\uff0cAST or ALT < 2.5 x Upper normality.\n\n          -  Signed consent\n\n        Exclusion Criteria:\n\n          -  Other malignancies simultaneously except in situ cervix or nonmelanoma skin cancer\n\n          -  Pregnancy or in lactation\n\n          -  HGB < 80 g/L, NEUT < 1.5x109 /L, PLT < 80x109 /L; CR \u2265 1.5 x Upper normality\uff0c TB \u2265\n             2.5 X Upper normality\uff0cAST or ALT  \u22652.5 x Upper normality\uff0cAKP \u2265 2.5 X Upper normality"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679327", 
            "org_study_id": "WY0524"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bevacizumab plus chemotherapy\uff08XELOX or FOLFOX\uff09", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug", 
                "other_name": "Eloxatin"
            }, 
            {
                "arm_group_label": "Bevacizumab plus chemotherapy\uff08XELOX or FOLFOX\uff09", 
                "intervention_name": "Xeloda", 
                "intervention_type": "Drug", 
                "other_name": "Capetabine"
            }, 
            {
                "arm_group_label": "Bevacizumab plus chemotherapy\uff08XELOX or FOLFOX\uff09", 
                "intervention_name": "Calcium folinate (CF)", 
                "intervention_type": "Drug", 
                "other_name": "Calcium folinate"
            }, 
            {
                "arm_group_label": "Bevacizumab plus chemotherapy\uff08XELOX or FOLFOX\uff09", 
                "intervention_name": "5-FU", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Bevacizumab plus chemotherapy\uff08XELOX or FOLFOX\uff09", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium, Dietary", 
                "Leucovorin", 
                "Bevacizumab", 
                "Levoleucovorin", 
                "Oxaliplatin", 
                "Capecitabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 5, 2012", 
        "location": {
            "contact": {
                "email": "Yihebalichi@yahoo.com", 
                "last_name": "Yihebali Chi, MD", 
                "phone": "8610-87788145"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Cancer Institute&Hospital Chinese Academy of Medical Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer", 
        "overall_official": [
            {
                "affiliation": "Chinese academy of medical science", 
                "last_name": "Yihebali Chi, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chinese academy of medical science", 
                "last_name": "Jinwan WANG", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "During the chemotherapy,all the patients demonstrate CT scan or MR to evaluate tumor response to therapy every two cycles.According to RECIST 1.1,tumor response was recorded.", 
            "measure": "Overall response rate", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679327"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "yihebali chi", 
            "investigator_title": "associated professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The start time point was defined as when patients receive the first cycle chemotherapy.The end time point was defined as When tumor response to therapy was evaluated as PD according to RECIST 1.1 or patients die for any reason.", 
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "From the time patients receive the first cycle chemotherapy to the time they die for any reason.", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Every cycle we demonstrate routine blood test,routine urine test,routine stool test,blood biochemical test.We recommend patients take blood pressure at least twice a week during the therapy.If needed,patients also need have electrocardiogram test and echocardiography.We will evaluate the toxicity according to CTCAE4.0", 
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }
        ], 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}